rasagiline (Azilect)

TVP-1022 is the (S)-isomer and a cardioprotective agent; monoamine oxidase type-B inhibitor that is not metabolized to amphetamine derivatives; can lead to fatal hypertensive crisis in patients who consume tyramine-rich foods

Also Known As:

Networked: 381 relevant articles (63 outcomes, 116 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Youdim, Moussa B H: 43 articles (11/2018 - 04/2002)
2.	Amit, Tamar: 31 articles (09/2015 - 10/2002)
3.	Bar-Am, Orit: 22 articles (09/2015 - 10/2002)
4.	Weinreb, Orly: 17 articles (01/2017 - 09/2004)
5.	Maruyama, Wakako: 14 articles (01/2020 - 06/2002)
6.	Hauser, Robert A: 12 articles (01/2022 - 08/2004)
7.	Poewe, Werner: 12 articles (01/2022 - 05/2005)
8.	Naoi, Makoto: 12 articles (01/2020 - 06/2002)
9.	Rascol, Olivier: 10 articles (10/2016 - 05/2005)
10.	Eyal, Eli: 9 articles (03/2019 - 11/2008)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/2013 - "Rapid onset of efficacy of rasagiline in early Parkinson's disease." 01/01/2008 - "Rasagiline improved HR-QOL as monotherapy in early Parkinson's disease (one study), but not clearly in more advanced disease (one study). " 09/01/2012 - "In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. " 01/01/2022 - "Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials." 06/01/2014 - "Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial."
2.	Fatigue 11/01/2015 - "Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003). " 10/08/2015 - "Rasagiline may be effective in reducing levels of physical fatigue in PD. " 11/01/2015 - "In this double-blinded, placebo-controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. " 11/01/2015 - "In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. " 01/01/2016 - "The studies demonstrated the effect of rasagiline on fatigue and cognitive functions in PD patients are described. "
3.	Disease Progression 01/01/2019 - "While the MSA-rasagiline study found no difference in the rates of clinical progression for patients treated with rasagiline versus placebo, it included a large, prospective magnetic resonance imaging (MRI) substudy that can provide new information on the underlying disease progression in patients with early MSA. " 03/26/2012 - "Although rasagiline showed neuroprotective properties both in vitro and in vivo, identifying its potential to slow clinical progression in the clinical setting has been elusive to date and was not definitively demonstrated in the studies discussed in this article. " 08/01/2009 - "One large trial has investigated the potential for disease modification in PD patients (Attenuation of Disease progression with Azilect Given Once-daily) and preliminary results maintain some possible advantage to earlier initiation of the 1 mg/day dose. " 01/01/2019 - "Rasagiline did not alter disease progression compared with controls over 12 months of treatment. " 10/01/2005 - "Preliminary results allow discussion of putative effects of rasagiline on some non-motor signs and disease progression. "
4.	Hypokinesia (Bradykinesia) 09/01/2011 - "Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. " 09/01/2011 - "To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity. " 09/01/2011 - "In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients. " 09/01/2011 - "As a monotherapy or an adjunctive therapy, rasagiline is an effective drug for reducing the severity of bradykinesia in PD patients." 09/01/2011 - "Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review."
5.	Starvation 02/01/2010 - "Based on the established cytoprotective and neuroprotective efficacies of propargylamine derivatives, as well as on our recent study showing that TVP1022 attenuates serum starvation-induced and doxorubicin-induced apoptosis in neonatal rat ventricular myocytes (NRVMs), we tested the hypothesis that TVP1022 will also provide protection against doxorubicin-induced NRVM functional derangements. " 09/01/2008 - "TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity." 09/01/2008 - "We specifically investigated the protective efficacy of TVP1022 and propargylamine in neonatal rat ventricular myocytes (NRVM) against apoptosis induced by the anthracycline chemotherapeutic agent doxorubicin and by serum starvation. " 09/01/2008 - "We demonstrated that pretreatment of NRVM cultures with TVP1022 or propargylamine attenuated doxorubicin-induced and serum starvation-induced apoptosis, inhibited the increase in cleaved caspase 3 levels, and reversed the decline in Bcl-2/Bax ratio. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Monoamine Oxidase (MAO)
3.	Selegiline (E250)
4.	Pramipexole (Mirapex)
5.	Mesylates (Mesylate)
6.	rasagiline (Azilect)
7.	propargylamine
8.	Doxorubicin (Adriamycin)
9.	entacapone (Comtan)
10.	TEMPO

Related Therapies and Procedures

1.	Therapeutics
2.	Activities of Daily Living (ADL)
3.	Microspheres (Microsphere)
4.	Drug Therapy (Chemotherapy)
5.	Transdermal Patch